Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Apr 13;8(1):5941.
doi: 10.1038/s41598-018-24397-w.

Safety of Low-calcium Dialysate and its Effects on Coronary Artery Calcification in Patients Undergoing Maintenance Hemodialysis

Affiliations
Clinical Trial

Safety of Low-calcium Dialysate and its Effects on Coronary Artery Calcification in Patients Undergoing Maintenance Hemodialysis

Yang Wen et al. Sci Rep. .

Abstract

To determine the safety of low-calcium-dialysate in patients undergoing maintenance hemodialysis (MHD) and its effects on coronary artery calcification (CAC) and analyze clinical risk factors for CAC. A total of 174 MHD patients were recruited and randomly divided into two groups: high-calcium dialysate (HCD, 1.5 mmol/L Ca2+) and low-calcium dialysate (LCD, 1.25 mmol/L Ca2+). Changes in CAC score (CACS) and cardiac function were evaluated using spiral computed tomography and echocardiography, respectively. Clinical and laboratory parameters were measured. Intra-dialysis adverse reactions were recorded and compared between the two groups. CACS was significantly lower in the LCD group than in the HCD group by the end of the study. Cardiac E/Amax was significantly higher in the LCD group than in the HCD group by the end of the study. There was no significant difference in the frequency of any intra-dialysis adverse reactions between the two groups during the study. LCD is helpful in maintaining cardiac diastolic function and postponing CAC progression. LCD does not increase intra-dialysis adverse reactions. Age may be the most important factor impacting CAC in MHD patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. USRDS 2016 Annual Data Report. Cardiovascular Disease in Patients with ESRD. National Institutes of Health, National Institute of Diabetes and Digestive and Diseases. http://www.usrds.org/2016/download/v2_c09_CVD_16.pdf (2016, Date of access: 02/03/2017).
    1. Dong Z. The Establishment of Chinese National Renal Data System and the Analysis on the Incidence and Treatment for Anemia in Hemodialysis Patients. Chinese people’s liberation army medical college. Thesis. (2012).
    1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–S119. doi: 10.1053/ajkd.1998.v32.pm9820470. - DOI - PubMed
    1. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial. 2003;16:101–105. doi: 10.1046/j.1525-139X.2003.16025.x. - DOI - PubMed
    1. Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin Dial. 2003;16:140–148. doi: 10.1046/j.1525-139X.2003.160301.x. - DOI - PubMed

Publication types